BrainsWay Reports First Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 05/17/23
Brainsway Ltd. Sponsored ADR (BWAY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 05/12/23
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious DepressionGlobeNewsWire • 03/28/23
BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational HighlightsGlobeNewsWire • 03/15/23
BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023GlobeNewsWire • 03/01/23
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™GlobeNewsWire • 01/11/23
BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben ShalomGlobeNewsWire • 12/13/22
BrainsWay Reports Third Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire • 11/16/22
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™GlobeNewsWire • 11/03/22
BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical AffairsGlobeNewsWire • 11/01/22
BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon ValleyGlobeNewsWire • 09/20/22
BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™GlobeNewsWire • 09/14/22
BrainsWay to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 08/31/22